Literature DB >> 19121350

Nanoparticles for nasal vaccination.

Noemi Csaba1, Marcos Garcia-Fuentes, Maria Jose Alonso.   

Abstract

The great interest in mucosal vaccine delivery arises from the fact that mucosal surfaces represent the major site of entry for many pathogens. Among other mucosal sites, nasal delivery is especially attractive for immunization, as the nasal epithelium is characterized by relatively high permeability, low enzymatic activity and by the presence of an important number of immunocompetent cells. In addition to these advantageous characteristics, the nasal route could offer simplified and more cost-effective protocols for vaccination with improved patient compliance. The use of nanocarriers provides a suitable way for the nasal delivery of antigenic molecules. Besides improved protection and facilitated transport of the antigen, nanoparticulate delivery systems could also provide more effective antigen recognition by immune cells. These represent key factors in the optimal processing and presentation of the antigen, and therefore in the subsequent development of a suitable immune response. In this sense, the design of optimized vaccine nanocarriers offers a promising way for nasal mucosal vaccination.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19121350     DOI: 10.1016/j.addr.2008.09.005

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  39 in total

1.  A poly(ethylene glycol)-based surfactant for formulation of drug-loaded mucus penetrating particles.

Authors:  Olcay Mert; Samuel K Lai; Laura Ensign; Ming Yang; Ying-Ying Wang; Joseph Wood; Justin Hanes
Journal:  J Control Release       Date:  2011-09-03       Impact factor: 9.776

Review 2.  Current prospects and future challenges for nasal vaccine delivery.

Authors:  Helmy Yusuf; Vicky Kett
Journal:  Hum Vaccin Immunother       Date:  2016-12-09       Impact factor: 3.452

Review 3.  Veterinary vaccine nanotechnology: pulmonary and nasal delivery in livestock animals.

Authors:  Daniella Calderon-Nieva; Kalhari Bandara Goonewardene; Susantha Gomis; Marianna Foldvari
Journal:  Drug Deliv Transl Res       Date:  2017-08       Impact factor: 4.617

Review 4.  Modulating the immune system through nanotechnology.

Authors:  Tamara G Dacoba; Ana Olivera; Dolores Torres; José Crecente-Campo; María José Alonso
Journal:  Semin Immunol       Date:  2017-10-09       Impact factor: 11.130

Review 5.  Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.

Authors:  Tewodros Mamo; E Ashley Moseman; Nagesh Kolishetti; Carolina Salvador-Morales; Jinjun Shi; Daniel R Kuritzkes; Robert Langer; Ulrich von Andrian; Omid C Farokhzad
Journal:  Nanomedicine (Lond)       Date:  2010-02       Impact factor: 5.307

Review 6.  Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases.

Authors:  Pan Tao; Jingen Zhu; Marthandan Mahalingam; Himanshu Batra; Venigalla B Rao
Journal:  Adv Drug Deliv Rev       Date:  2018-07-06       Impact factor: 15.470

7.  Cationic liposome-hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigens.

Authors:  Yuchen Fan; Preety Sahdev; Lukasz J Ochyl; Jonathan Akerberg; James J Moon
Journal:  J Control Release       Date:  2015-04-11       Impact factor: 9.776

Review 8.  Progress towards a needle-free hepatitis B vaccine.

Authors:  Filipa Lebre; Gerrit Borchard; Maria Conceição Pedroso de Lima; Olga Borges
Journal:  Pharm Res       Date:  2010-11-19       Impact factor: 4.200

Review 9.  Perspective on Nanoparticle Technology for Biomedical Use.

Authors:  Ramesh Raliya; Tandeep Singh Chadha; Kelsey Haddad; Pratim Biswas
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

10.  Bronchus-associated lymphoid tissue (BALT) and survival in a vaccine mouse model of tularemia.

Authors:  Damiana Chiavolini; Javier Rangel-Moreno; Gretchen Berg; Kate Christian; Laura Oliveira-Nascimento; Susan Weir; Joseph Alroy; Troy D Randall; Lee M Wetzler
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.